8. Recursion Pharmaceuticals Inc. (NASDAQ:RXRX)
If there is one company that fully embraces the concept of AI-first drug discovery, it is Recursion Pharmaceuticals Inc.. Positioned at the intersection of big data, machine learning, and biotechnology, Recursion is not just participating in the AI healthcare revolution—it is attempting to redefine it.
The company’s recent expansion of its partnership with Citeline highlights a critical trend in artificial intelligence in healthcare: the increasing importance of real-world data. By integrating advanced analytics into its platform, Recursion aims to improve clinical trial design, optimize decision-making, and ultimately reduce the staggering costs associated with bringing new drugs to market.
Unlike traditional biotech firms, Recursion operates more like a technology company with a pharmaceutical output. Its pipeline is extensive, supported by partnerships with global giants such as Roche, Merck, Bayer, and Sanofi. This network effect is crucial, as it validates the scalability of its AI-driven platform.
Financially, the company is well-positioned, ending 2025 with over $754 million in cash—enough to sustain operations into 2028. Add to that more than $500 million already received in milestone payments, and the picture becomes clearer: Recursion is building a long-term AI ecosystem rather than chasing short-term approvals.
For investors targeting best medical AI stocks with high upside, the nearly 94% projected upside potential underscores both the opportunity and the inherent risk. This is not a defensive play—it is a high-conviction bet on the future of AI-powered drug discovery platforms.
Click next to see the following stock...
